Press Releases April 28, 2026 08:30 AM

T3 Defense CEO Converts $2.14 Million of Debt into Equity, Reducing Outstanding Debt and Strengthening Balance Sheet

T3 Defense CEO converts $2.14 million debt into equity, strengthening company balance sheet and aligning leadership interests

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
DFNS

T3 Defense Inc. announced that its CEO and Chairman, Menachem Shalom, has converted $2.14 million of promissory notes into approximately 4.1 million restricted shares of common stock. This conversion eliminates near-term debt repayment obligations, improves the capital structure, and aligns the CEO’s interests with shareholders. The move comes amid the company's ongoing strategy to build a diversified portfolio in critical defense technology sectors.

T3 Defense CEO Converts $2.14 Million of Debt into Equity, Reducing Outstanding Debt and Strengthening Balance Sheet
DFNS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • CEO Menachem Shalom converted $2.14 million debt into equity, receiving 4.1 million restricted shares.
  • This transaction reduces outstanding debt and near-term financial obligations, strengthening T3 Defense's balance sheet.
  • T3 Defense continues to grow its portfolio across defense sectors including missile defense, autonomous navigation, and electronic warfare.

NEW YORK and NETANYA, Israel, April 28, 2026 (GLOBE NEWSWIRE) -- T3 Defense Inc. (Nasdaq: DFNS) (“T3 Defense” or the “Company”), a defense technology holding company that acquires and operates mission-critical defense companies, today announced that its Chairman and Chief Executive Officer, Menachem Shalom, has voluntarily converted promissory notes held by him in an aggregate principal amount of approximately $2.14 million into approximately 4.1 million restricted shares of the Company’s common stock.

The conversion eliminates approximately $2.14 million of outstanding debt, reducing near-term repayment obligations and improving the Company’s overall capital structure. Mr. Shalom elected to exchange the right to cash repayment for equity in the Company’s stock, amounting to 4.1 million restricted shares, further aligning his interests with those of shareholders.

“I chose to convert these notes into equity rather than take repayment because I believe our capital is better deployed strengthening the Company and supporting execution,” said Mr. Shalom, Chairman and CEO of T3 Defense. “I believe deeply in the value and potential of T3 Defense. This transaction removes debt from the balance sheet while increasing my ownership, further realigning my interest with shareholders. I expect our progress to be demonstrated through execution, and I have positioned my capital accordingly.”

The note conversion follows a period of significant operational momentum for T3 Defense, which continues to execute on its strategy of building a diversified portfolio of defense technology companies spanning critical domains including missile defense, autonomous navigation, electronic warfare, and tactical infrastructure. The transaction is intended to simplify the Company’s balance sheet and remove near-term financial obligations, providing greater flexibility to support ongoing operations and execution across its portfolio companies.

The shares issued in connection with the conversion are subject to applicable securities laws and regulations.

About T3 Defense Inc.

T3 Defense Inc. (NASDAQ: DFNS), is a holding company that acquires and operates mission-critical defense businesses involved in national security programs. It focuses on manufacturers with strong customer relationships and solid order backlogs, often capacity-and resource-constrained and specialized areas such as drones and autonomous vehicles, counter-drone systems, advanced manufacturing, tactical robotics, and AI software and system integration. Through disciplined acquisitions, centralized capital and strategy, and decentralized day-to-day operations, T3 Defense aims to strengthen essential defense capabilities and build long-term value.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements include, but are not limited to, statements regarding T3 Defense Inc.’s growth strategy; its ability to expand manufacturing throughput, industrial capacity, and production reliability; anticipated benefits of recent executive appointments; expectations regarding subsidiary coordination and operational scalability; the conversion of backlog into repeatable production output; and the Company’s ability to capitalize on structural constraints within the defense industrial base.

Forward-looking statements are based on current expectations, estimates, and projections and involve known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied in such statements. These risks and uncertainties include, among others, risks related to defense program funding and timing; dependence on government contracts and defense OEM relationships; supply chain constraints; manufacturing execution risks; integration of acquired businesses; availability of capital; and general economic and geopolitical conditions. Readers are encouraged to review the Company’s filings with the Securities and Exchange Commission for a discussion of additional risk factors.

T3 Defense undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

T3 Defense Inc.
575 5th Avenue
New York, NY 10017
[email protected]
www.t3dfns.com

Investor Relations
The Equity Group Inc.
Lena Cati
[email protected]
+1 (212) 836-9611

Val Ferraro
[email protected]
+1 (212) 836-9633


Risks

  • Dependence on government contracts and defense OEM relationships could impact revenues.
  • Supply chain constraints and manufacturing execution risks could affect operational performance.
  • Integration of acquired businesses and geopolitical conditions present uncertainties to company growth.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026